Enteric fever, predominantly caused by Salmonella Typhi and Paratyphi, remains a significant health concern worldwide. This article provides an updated approach to the diagnosis and treatment of enteric fever, incorporating recent advancements in medical science.
Early diagnosis of enteric fever is crucial for effective management. The gold standard for diagnosis remains blood culture, which has a sensitivity of 40-60%. However, this method is limited by the need for sophisticated laboratories and slow turnaround times. Recent advancements include the introduction of rapid diagnostic tests (RDTs) such as the Typhidot and Tubex TF, which are based on detecting IgM antibodies against the bacteria. These RDTs have shown promising results in endemic regions, with higher sensitivity and specificity compared to traditional methods.
Treatment of enteric fever has been complicated by the emergence of multidrug-resistant strains. The World Health Organization currently recommends ceftriaxone or cefixime for uncomplicated cases, and ciprofloxacin for complicated cases. However, due to increasing resistance, azithromycin has emerged as a viable alternative. Adjunctive therapies, such as probiotics and zinc supplementation, are also being explored to reduce the duration and severity of illness.
Prevention strategies are key in controlling the spread of enteric fever. Vaccination remains the most effective measure, with the Vi polysaccharide and Ty21a vaccines showing good efficacy. In addition, improving water quality, sanitation, and hygiene practices are crucial in endemic regions to reduce transmission.
Enteric fever continues to present significant challenges in diagnosis and treatment. Incorporating rapid diagnostic tests into clinical practice and exploring alternative treatment options, such as azithromycin, may improve patient outcomes. A multifaceted approach encompassing prevention strategies, including vaccination and improved sanitation, is essential to control the spread of this disease.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation